EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

High-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial

Vinicius A Schoeps iD, Raviola Murataj, Akash Virupakshaiah iD, Carson E Moseley, Kristen M Krysko iD, Bardia Nourbakhsh iD, Ferhan Qureshi, Roland Henry, Emmanuelle Waubant

Multiple Sclerosis Journal · 11.06.2026

DOI: 10.1177/13524585261454840 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Multiple Sclerosis Journal, online erschienen am 11.06.2026. Verfasst von Vinicius A Schoeps und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California, San Francisco, San Francisco, California, USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Multiple Sclerosis Society, Race to Erase MS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To assess whether oxidative stress drives biomarkers implicated in disability progression independent of relapses, we randomized 2:1 fifteen adults with progressive MS (Expanded Disability Status Scale (EDSS): 2.0–6.5) to receive high-dose oral N -acetyl cysteine (NAC, 1250 mg TID), a major source of endogenous antioxidants, or placebo for 4 weeks (NCT02804594). Using the Olink proximity extension assay, we measured 20 serum biomarkers at baseline and 4 weeks on treatment. NAC resulted in decreased glial fibrillary acidic protein (median change: −10.1 pg/mL vs. 39.5 pg/mL, p = 0.008) alongside stable neurofilament light chain levels (median change: 0.25 pg/mL vs. 0.61 pg/mL, p = 0.777). Our exploratory biomarker findings suggest NAC may be a promising agent to delay MS progression.

Schlagwörter

Stichwörter der Autor:innen

N-acetyl cysteineclinical trialoxidative stressprimary progressive multiple sclerosissecondary progressive multiple sclerosis

Autor:innen und Institutionen

  • Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
  • Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada; Division of Neurology, Department of Medicine, St. Michael's Hospital, Toronto, ON, Canada; Li Ka Shing Knowledge Institute, Tor…
  • Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
  • Octave Bioscience, Menlo Park, CA, USA.

ORCID-Profile: Vinicius A Schoeps, Akash Virupakshaiah, Kristen M Krysko, Bardia Nourbakhsh

Förderung

  • National Multiple Sclerosis Society
  • Race to Erase MS

Zitieren

APA

Schoeps, V. A., Murataj, R., Virupakshaiah, A., Moseley, C. E., Krysko, K. M., Nourbakhsh, B., Qureshi, F., Henry, R., & Waubant, E. (2026). High-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial. Multiple Sclerosis Journal. https://doi.org/10.1177/13524585261454840

Vancouver

Schoeps VA, Murataj R, Virupakshaiah A, Moseley CE, Krysko KM, Nourbakhsh B, et al. High-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial. Multiple Sclerosis Journal. 2026. doi:10.1177/13524585261454840

BibTeX
@article{Schoeps2026,
  author = {Schoeps, Vinicius A and Murataj, Raviola and Virupakshaiah, Akash and Moseley, Carson E and Krysko, Kristen M and Nourbakhsh, Bardia and Qureshi, Ferhan and Henry, Roland and Waubant, Emmanuelle},
  title = {High-dose N -acetyl cysteine reduces GFAP levels: Exploratory results from a pilot double-blind, placebo-controlled randomized trial},
  journal = {Multiple Sclerosis Journal},
  year = {2026},
  doi = {10.1177/13524585261454840}
}
Kostenlos starten →